DISCOVERing Treatment Reality of Type 2 Diabetes in Real World Settings (DISCOVER)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02322762|
Recruitment Status : Completed
First Posted : December 23, 2014
Last Update Posted : June 9, 2022
|Condition or disease|
|Type 2 Diabetes Mellitus|
|Study Type :||Observational|
|Actual Enrollment :||15992 participants|
|Official Title:||DISCOVERing Treatment Reality of Type 2 Diabetes in Real World Settings|
|Actual Study Start Date :||December 30, 2014|
|Actual Primary Completion Date :||August 21, 2019|
|Actual Study Completion Date :||August 21, 2019|
One single cohort.
One single cohort of patients with type 2 diabetes mellitus initiating their second line anti-diabetic therapy after first line anti-diabetic therapy.
- Anti-diabetic treatments prescribed by physicians in a real-world setting. [ Time Frame: Up to 3 Years ]The drugs (or their combinations) prescribed by physicians to patients initiating a 2nd line anti-diabetic treatment in a real-world setting will be described at inclusion and during 3 years follow-up.
- Disease control in terms of achieving HbA1c target goals and reducing body weight and blood pressure. [ Time Frame: Up to 3 years ]
- Changes in anti-diabetic treatments [ Time Frame: Up to 3 years ]
- Disease progression (incidence of microvascular and macrovascular complications). [ Time Frame: Up to 3 years ]
- Incidence of hypoglycemic events. [ Time Frame: Up to 3 years ]
- Quality of Life, using Patient Reported Outcomes questionnaires. [ Time Frame: Up to 3 years ]
- Use of Healthcare resources. [ Time Frame: Up to 3 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02322762
|Study Director:||Jesus Medina, PhD||AstraZeneca|
|Principal Investigator:||Linong Ji, MD||Peking University People's Hospital, China|
|Principal Investigator:||Bong Soo Cha, Dr.||Severance Hospital, Yonsei University Health System|